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Abstract
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity
and mortality worldwide. Although it is considered both preventable and treatable,
COPD still represents an important public health challenge. The classes of pharmaco-
logical agents widely used for the maintenance treatment are bronchodilators (SABA,
SAMA, LABA, LAMA) and inhaled corticosteroids (ICS). While it is largely accepted
that inhaled bronchodilators, which are effective and well tolerated in patients with
stable disease, are the cornerstone of the pharmacological management of COPD,
there is an ongoing debate regarding the role of inhaled corticosteroids. This is also
reflected in the last versions of the GOLD recommendations, which suffered dramatic
changes in the recent years. The trend for personalized medicine led to the search for
biomarkers which could guide the therapeutic decisions. Recent studies demonstrated
that blood eosinophils can reasonably predict the ICS relative efficacy in preventing
COPD exacerbations and thus could inform the disease management.
Keywords: COPD, lung function, exacerbation, bronchodilators, corticosteroids,
biomarkers, eosinophils
1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a common condition, usually
affecting people of >40 years of age significantly exposed to noxious particles or
gases [1]. Although considered both preventable and treatable [1], COPD remains a
leading cause of morbidity and mortality [2, 3], affecting an estimated 384 million
people worldwide [4]. The COPD prevalence is projected to increase in the coming
decades [5], as well as its position among the leading causes of mortality [4].
Active or passive cigarette smoking is the most commonly encountered risk
factor for COPD across the world [1]; however other factors may play a role in the
disease pathogenesis, such as genetic factors [6, 7], exposure to indoor and outdoor
air pollutants [8–11], exposure to occupational dusts, chemical agents or fumes [12],
infections (HIV, tuberculosis) [13, 14], and socioeconomic status [15].
The normal lung response to the inhalation of noxious factors is an inflammatory
reaction of the airways. In patients who develop COPD, the excessive inflammatory
response is further enhanced by the oxidative stress and an imbalance of the
protease-antiprotease system, leading to the destruction of the lung parenchyma
and disruption of normal repair and defense mechanisms. Emphysema and small
airway fibrosis are the consequences of these processes, which translate into gas
trapping and chronic airflow limitation [1].
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By definition, COPD is a chronic condition, and the major symptoms exhibited
by the patients suffering from this disease, dyspnea, cough, and sputum produc-
tion, are usually persistent and/or progressive and have a considerable negative
effect on the patient’s quality of life. The Global Burden of Disease Study
highlighted that COPD is a major contributor to disability and mortality around the
world, by ranking COPD as the fifth leading cause of disability-adjusted life years
(DALYs) lost in 2013 [16].
The natural course of the disease is grafted by acute episodes of worsening of
symptoms triggered by infectious agents, air pollution, and other factors. These
events are referred to as “exacerbations” and usually require a change in medication
and/or hospitalization. Exacerbations are associated with accelerated lung function
decline, reduced quality of life, and increased mortality [17] and, not surprisingly,
have been surnamed as “chest attacks” or “strokes of the lung” [18, 19].
2. Pharmacological treatment in stable COPD
The main goals for the management of stable COPD are improvement in quality
of life by relieving symptoms and increasing exercise tolerance and reduction of
mortality risk by preventing exacerbations and disease progression [1].
Several inhaled, oral, and systemically administered drugs improve lung func-
tion, decrease the frequency and severity of COPD exacerbations, and improve
patients’ quality of life [20].
Non-pharmacological therapies in COPD, including smoking cessation strate-
gies, pulmonary rehabilitation, vaccinations, surgical or bronchoscopic interven-
tions, and noninvasive ventilation have their established role in the management of
the disease; however they are not discussed here, as the focus of this chapter is on
the pharmacological treatment.
Back in 2001 when the first edition of the GOLD document was released [21],
the pharmacological arsenal for the treatment of COPD was rather limited, com-
prising of short-acting beta2-agonists and anticholinergics, long-acting beta2-ago-
nists, theophyllines, and mucoactive agents. Inhaled corticosteroids, although
available as single medication, were never widely recommended for the treatment
of COPD in monotherapy and have no current authorization for use outside fixed-
dose combinations.
Nowadays, there is a broader range of molecules recommended for the treat-
ment of stable COPD that can be classified in the following classes of pharmacolog-
ical agents:
• Beta2-agonists: short-acting (SABA) and long-acting (LABA)
• Anticholinergics: short-acting (SAMA) and long-acting (LAMA)
• Fixed-dose combinations: SABA/SAMA, LABA/ICS, LABA/LAMA, LABA/
LAMA/ICS
• Methylxanthines
• Phosphodiesterase-4 (PDE4) inhibitors
• Mucolytics
• Antibiotics
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Additionally, a new acquisition in the bronchodilator portfolio could be the
potential use of dual agents or bifunctional muscarinic antagonists and beta2-ago-
nists (MABAs), which combine both antimuscarinic and adrenergic properties in a
single molecule [22]. Some of these molecules are already in clinical trials, but a
major caveat is the difficulty to balance the antimuscarinic and adrenergic activities,
without expressing a tendency toward one of them [23].
Efforts have been made for the discovery of new pharmacological agents, either
belonging to the mentioned classes or addressing new therapeutic targets: new
corticosteroids, novel classes of bronchodilators, kinase inhibitors, mediator antag-
onists (including biological therapies, such as cytokine inhibitors), antioxidants,
etc. Unfortunately, many of these molecules never made it to the market or were
not granted approval for COPD due to safety, efficacy, or delivery issues; several
others are still in the development process [23].
Currently available pharmacological agents and other therapies are mainly used
as pathogenic or symptomatic treatment.
2.1 Improvement of lung function and symptoms
Chronic airflow limitation is a central characteristic of COPD and is the result of
the combination in varying degrees of several pathological processes such as
narrowing of the airways, mucus hypersecretion, and loss of small conducting
airways [24]. The consequences of these anatomic changes are expiratory airflow
limitation, air trapping, and ventilation-perfusion mismatch [22, 25]. Additionally,
the loss of elastic recoil and hyperinflation adversely affect thoracic and diaphrag-
matic mechanics, increasing the work of breathing and ultimately leading to
dynamic hyperinflation [26]. Hyperinflation is an independent predictor of mortal-
ity in COPD [27].
The clinical expression of airflow limitation is chronic, progressive dyspnea,
which typically worsens with physical exercise. Chronic cough with or without
sputum production is usually a reflection of the ongoing inflammatory process in
the airways of COPD patients. However, there is no linear correlation between the
severity of the airflow limitation and the level of symptoms. Some patients may
have little subjective complaints, although the lung function testing reveals various
degrees of airflow limitation, while other patients may have significant complaints,
with little or no evidence of airflow obstruction [28]. In some cases, the symptoms
may precede the development of airflow limitation by many years [1].
Treatment with inhaled bronchodilators can reduce hyperinflation, improve
dyspnea, and increase exercise tolerance [29], and therefore, bronchodilators are
considered as a cornerstone in the management of stable COPD [30].
While short-acting bronchodilators are an option for patients with occasional
dyspnea at low risk of exacerbations, the majority of patients have breathlessness
leading to exercise limitation at the time of diagnosis and may require more inten-
sive treatment than short-acting bronchodilators alone [30]. For these patients,
whether or not they are also at higher risk of exacerbations, long-acting bronchodi-
lators (as monotherapy or in combination) are recommended as a preferred treat-
ment choice in the GOLD strategy report [1].
Airway tone is controlled by both the sympathetic and parasympathetic nervous
systems. These mechanisms interact and may potentiate each other and are
employed alone or in combination therapeutically. Relaxation of airway smooth
muscle is caused by blockade of acetylcholine activity at the receptor (muscarinic
antagonist) or stimulation of the G protein-coupled receptor (beta-agonist) [31].
Anticholinergic drugs in the form of smoked alkaloids were among the first
effective treatments for asthma [32]. In the mid-twentieth century, parenteral
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muscarinic antagonists and beta-agonists were used for acute attacks of asthma
[33]. The major disadvantages of the systemic delivery were the side effects and a
short duration of benefit. As such, subsequent work has both optimized the receptor
specificity and the duration of action [22].
Beta-agonists were in use in Chinese medicine for millennia in the form of
ephedra. Developments in the mid-twentieth century yielded compounds that spe-
cifically target the beta2-adrenergic receptor, reducing the side effects from beta1-
agonists [31].
Since the approval by the US Food and Drug Administration (FDA) in 2004 of
the first LAMA, tiotropium, long-acting bronchodilators have begun to play a
central role in the management of stable COPD. Currently available molecules for
inhalation delivery are summarized in Table 1.
The benefits of long-acting bronchodilator monotherapy have been well proven
across a range of clinical studies [30] and include improvement of the airflow
limitation [34–39], dyspnea [34, 35, 39], physical activity/exercise capacity
[29, 40–42], health status [34, 35, 37–39], and prevention of exacerbations [35, 39,
43, 44]; however, many patients remain symptomatic despite treatment [45].
Dual bronchodilation improves lung function compared with a single broncho-
dilator [30]. Long-acting beta2-agonists and long-acting muscarinic antagonists act
via different mechanisms; when used together in patients with COPD, they exert
additional bronchodilating effects [46]. Multiple studies have assessed [30] and
demonstrated that the use of LABA/LAMA dual bronchodilation results in addi-
tional improvements in lung function, exacerbation rates, health status, and other
outcome measures when compared with monobronchodilation, while the safety
profile of the dual bronchodilators was similar to that observed with placebo and
individual monocomponents. Currently available LABA/LAMA combinations are
listed in Table 2.
According to current guidelines and strategy reports, long-acting bronchodila-
tors in monotherapy are adequate options for the majority of COPD patients,
regardless of the disease severity. However, in the GOLD report 2019 [1], the
authors provide a clarification of the concept of “escalation” and “de-escalation” of
the COPD therapy, which was introduced in a previous version. While “de-
escalation” is mainly employed for the withdrawal of ICS due to lack of response or
Delivery type Duration of action (h)
Long-acting beta2-agonists (LABA)
Arformoterol Nebulized 12
Formoterol DPI 12
Indacaterol DPI 24
Olodaterol SMI 24
Salmeterol MDI, DPI 12
Long-acting anticholinergics (LAMA)
Aclidinium bromide DPI, MDI 12
Glycopyrronium bromide DPI 12–24
Tiotropium DPI, SMI 24
Umeclidinium DPI 24
DPI = dry powder inhaler; MDI = metered dose inhaler; SMI = soft mist inhaler.
Table 1.
Currently available LABAs and LAMAs as monotherapy.
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side effects, such as pneumonia, the “escalation” of treatment should be prompted
by either inappropriate symptomatic response to the initial therapy or by the pres-
ence of exacerbations despite regular treatment and consists of adding a second
class of bronchodilator and/or an ICS and/or other pharmacological agents
(azithromycin, roflumilast) in order to ensure maximal symptom relief and to curb
the risk of exacerbations.
The choice of the bronchodilator treatment should take into account several
factors, such as physiological impairment, symptom burden, and exacerbation risk,
and should be individualized according to the drug safety profile, cost, and patients’
preference for device and medication [1, 20].
One of the current controversies in COPD [20] is the following: what is best, a
progressive escalation of bronchodilator therapy or “maximizing” bronchodilator
therapy with dual bronchodilator therapy ab initio? The members of the GOLD
Scientific Committee suggest that ensuring a maximal bronchodilation from the
beginning could be a reasonable approach for both patients with high symptom
burden and patients less severely affected. The latter may underreport their symp-
toms, masking an underlying resting and exercise lung hyperinflation, which is
further linked to increased mortality and risk of severe exacerbations [20]. How-
ever, if a single agent is preferred, currently available evidence supports the use of a
LAMA (tiotropium) since it improves lung function and health status even in
patients with milder disease [47].
2.2 Prevention of exacerbations
COPD exacerbations represent acute worsening of symptoms requiring changes
in medication and/or hospitalization [1]. Anthonisen and colleagues’ criteria [48]
have been used for decades now in an attempt to standardize the evaluation of these
events; however COPD exacerbations still have no universally established definition
[49] and are subject to diagnostic uncertainty [50].
Historically, the level of healthcare resource use (HCRU) required for the man-
agement of COPD exacerbations was used both to define and quantify the severity
of the exacerbations, with moderate exacerbations requiring administration of oral
steroids and/or antibiotics and severe exacerbations requiring hospitalization
[49, 51–53]. However, healthcare use in COPD varies widely depending on access,
leading to disparities across different healthcare systems [54]. Furthermore, in
order to be treated, an acute event should be reported to healthcare professionals;
hence unreported events may not be captured by HCRU definitions. In some
reports, such events comprise up to two-thirds of exacerbations and can impair
health-related quality of life [55, 56] and increase the risk of hospitalization [57].
Delivery type Duration of action (h)
Fixed-dose combinations of LABA and LAMA (LABA/LAMA)
Formoterol/Aclidinium DPI 12
Formoterol/Glycopyrronium MDI 12
Indacaterol/Glycopyrronium DPI 12–24
Olodaterol/Tiotropium SMI 24
Vilanterol/Umeclidinium DPI 24
DPI = dry powder inhaler; MDI = metered dose inhaler; SMI = soft mist inhaler.
Table 2.
Currently available fixed-dose combinations of LABA/LAMA.
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Another approach to define exacerbations is based on the systematic and stan-
dardized assessment of daily symptoms recorded using specific questionnaires
(diaries) administered to the patients on paper or electronically. These question-
naires were developed with the ability to detect worsening of symptoms beyond a
pre-specified threshold, based on patients’ reporting of their daily symptoms
[58, 59]. Advantages of a standardized, validated assessment of COPD symptoms in
exacerbation studies include uniform metrics, reduced recall bias, and the ability to
fully characterize exacerbations of COPD, including the estimated 50–70% of
events that are unreported [55, 56, 59]. Although attractive, this kind of approach is
more difficult to implement outside the clinical trial setting, and the concordance
with the HCRU-defined events is modest [54, 60].
COPD exacerbations have a marked negative effect on both the patient and
underlying disease processes [61] and can result in hospitalization and readmission,
an increased risk of death [62], and a significant reduction in health status [55].
Exacerbations are also associated with long-term decline in lung function and a high
socioeconomic cost [63, 64]. A history of frequent exacerbations is a good predictor
for future exacerbation risk and defines the “frequent exacerbator” phenotype [65].
Thus, optimizing the prevention and management of COPD exacerbations are
important clinical issues [61].
The GOLD strategy report stratifies COPD patients based on the severity of their
airflow limitation, symptom burden, and the risk of exacerbations; however the
recommendations for the pharmacological treatment rely exclusively on the level of
symptoms and exacerbation risk [1].
While the initial assessment of exacerbation risk may be biased by the patients’
ability to recall historical episodes of symptom worsening prior to being diagnosed
with COPD, the reassessment of risk after initial pharmacological treatment should
be able to identify patients requiring an escalation of treatment for a better preven-
tion of future exacerbation episodes.
The preferred treatment options for patients at high risk of exacerbation are a
LAMA in monotherapy, a LABA/LAMA, or a LABA/ICS combination [1].
There is evidence that both LABAs and LAMAs significantly improve the exac-
erbation rate versus placebo [66–68]; however, clinical trials have shown a greater
effect on exacerbation rates for LAMA treatment (tiotropium) versus LABA treat-
ment [69, 70].
There is a strong evidence that treatment with fixed-dose combinations of
LABA/LAMA improves lung function, symptoms, and health-related quality of life
compared to placebo or its individual bronchodilator components [71–73]. The
superiority of dual bronchodilation in the prevention of exacerbations compared to
monocomponents was demonstrated for a LABA/LAMA combination [74], while
another large study found that combining a LABA with a LAMA did not reduce
exacerbation rate as much as expected compared to LAMA alone [75].
Similarly, an ICS combined with a LABA is more effective than the individual
components in improving lung function and health status and reducing exacerba-
tions in patients with a history of exacerbations and moderate to very severe COPD
[76, 77]. Currently available ICS/LABA combinations are listed in Table 3.
Furthermore, another study demonstrated the superiority of a LABA/LAMA
combination versus an ICS/LABA combination in the prevention of exacerbations
in patients with moderate to very severe COPD and a history of exacerbations,
regardless of baseline blood eosinophils [78].
In a recently published review, a group of experts critically evaluated mecha-
nisms potentially responsible for the increased benefit of LABA/LAMA combina-
tions over single long-acting bronchodilators or LABA/inhaled corticosteroids in
decreasing exacerbation. These included effects on lung hyperinflation and
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mechanical stress, inflammation, excessive mucus production with impaired
mucociliary clearance, and symptom severity [79].
Although triple therapy in separate inhalers is already in use for COPD patients
for a couple of years now, fixed triple therapy combining an ICS, a LABA, and a
LAMA in a single inhaler recently emerged on the market. Currently, there are only
two products approved by the European Medicines Agency (EMA) for use in
COPD, and a third one was recently approved in Japan (see Table 4) [80].
Several recent studies have demonstrated that single-inhaler triple therapy is
more effective in reducing the exacerbation than LAMA alone, a LABA/ICS, or a
LABA/LAMA combination [81–84].
The GOLD algorithm for the escalation of treatment in patients with persistent
risk of exacerbations despite regular treatment provides that patients taking a single
bronchodilator should be switched to dual bronchodilation and then to triple ther-
apy and/or additional therapies. Alternatively, some patients with high blood
eosinophils may benefit from a LABA/ICS combination prior to receiving triple
therapy [1].
The use of ICS in COPD has become very controversial in the last years, owing
on the one hand to the limited effect on lung function and on the other hand to
potential side effects associated with long-term use at the higher doses
recommended for the treatment of COPD. These include:
• Risk of infections such as pneumonia [85], tuberculosis and non-tuberculous
mycobacterial disease [86], and oropharyngeal candidiasis [87]
• Skin lesions [88]
• Diabetes onset and progression [89]
Delivery type Duration of action (h)
Fixed-dose combinations of LABA and ICS (LABA/ICS)
Formoterol/Beclometasone MDI 12
Formoterol/Budesonide MDI, DPI 12
Formoterol/Mometasone MDI 12
Salmeterol/Fluticasone MDI, DPI 12
Vilanterol/Fluticasone furoate DPI 24
DPI = dry powder inhaler; MDI = metered dose inhaler.
Table 3.
Currently available fixed-dose combinations of LABA/ICS.
Delivery type Duration of action (h)
Fixed-dose combinations of LABA, LAMA and ICS (LABA/LAMA/ICS)
Formoterol/Glycopyrronium/Beclometasone MDI 12
Vilanterol/Umeclidinium/Fluticasone furoate DPI 24
Formoterol/Glycopyrronium/Budesonide MDI 12
DPI = dry powder inhaler; MDI = metered dose inhaler.
Table 4.
Currently available fixed-dose combinations of LABA/LAMA/ICS.
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• Increased risk of bone fractures [90]
• Cataracts [91]
The use of ICS alone is discouraged in COPD [20]; however several studies have
demonstrated a consistent effect on exacerbation reduction of LABA/ICS fixed-dose
combinations versus individual monocomponents [76, 77, 87, 92, 93].
The need for biomarkers accurately assessing disease activity and response to
therapy in order to develop better COPD treatment is well acknowledged [94].
Peripheral blood eosinophil level has emerged in the recent years as a promising
biomarker, showing capabilities to predict both the risk of exacerbation and the
magnitude of response to ICS therapy [95–97]. Thus, several post hoc or pre-specified
analyses of clinical trials have shown that blood eosinophil levels may indicate which
patients can benefit from a reduction of exacerbations by the treatment with ICS-
containing regimens [84, 96, 98]. Various cutoff points were proposed for the level of
blood eosinophils in order to identify the patients who would benefit most from the
ICS therapy. A recent pooled analysis (n = 4528) evidenced that a level of blood
eosinophils >300/mmc3 suggests a beneficial role of ICS, while a low level of blood
eosinophils (<100/mmc3) may be a negative predictor of the ICS effects. This was
previously observed in other two post hoc analyses [99, 100] and was confirmed in a
pre-specified analysis of another randomized clinical trial [101].
Other classes of pharmacological agents, such as PDE4-inhibitors (roflumilast)
or antibiotics (azithromycin) administered orally on top of inhaled therapy, may
bring an additional benefit in reducing exacerbations [102, 103]. The side effects,
however, limit their use to selected patients only.
2.3 Mortality risk
Two large clinical trials have failed to demonstrate a positive effect of the active
treatments (LABA/ICS, ICS alone, and LABA alone) versus placebo on the mortality
risk [36, 104].
Smoking cessation, vaccinations, supplemental oxygen for hypoxemic patients,
and lung volume reduction surgery in selected patients are the only therapies that
have been proven to improve survival; smoking cessation also attenuates disease
progression [20].
3. Conclusions
Inhaled long-acting bronchodilator treatment plays a central role in the man-
agement of stable COPD. Anti-inflammatory treatment with inhaled corticosteroids
in combination with a long-acting beta2 agonist or with dual bronchodilation
(LABA and LAMA) as part of the triple therapy improves outcomes especially in
patients with high blood eosinophil level.
Despite all the progress made in the recent years in the field of COPD, we are
still lacking drugs that can effectively modify the course of the disease [23].
The unmet needs in COPD warrant further research for the discovery of new
biomarkers and effective therapeutic agents able to radically improve short-term
and long-term outcomes in patients suffering of this disease.
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